Cystic Fibrosis Foundation Therapeutics Extends Drug Development Collaboration with Proteostasis Therapeutics
March 4, 2014
Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT) announced it will extend funding for continued collaboration with Proteostasis Therapeutics, Inc., for the development of new therapies to treat the most common CF mutation, Delta F508.